Complement regulation at necrotic cell lesions is impaired by the age-related macular degeneration-associated factor-H His402 risk

Journal of Immunology

Volumn 187, Issue 8, 2011, Pages 4374-4383

  Lauer, Variant Nadine ^a   Mihlan, Michael ^a   Hartmann, Andrea ^a   Schlötzer Schrehardt, Ursula ^b   Keilhauer, Claudia ^c   Scholl, Hendrik P N ^d,e   Issa, Peter Charbel ^d,h   Holz, Frank ^d   Weber, Bernhard H F ^f   Skerka, Christine ^a   Zipfel, Peter F ^a,g  

^a HANS KNÖLL INSTITUTE   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^d UNIVERSITY HOSPITAL BONN   (Germany)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f UNIVERSITY OF REGENSBURG   (Germany)

^g FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^h UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; COMPLEMENT FACTOR H; HISTONE; LIPOCORTIN 5; PROTEIN FHL1; TUMOR NECROSIS FACTOR ALPHA; TYROSINE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ADHESION; CELL DAMAGE; CELL DEATH; CELL SURFACE; COMPLEMENT INHIBITION; COMPLEMENT SYSTEM; COMPLEX FORMATION; CONTROLLED STUDY; CYTOKINE RELEASE; GENETIC RISK; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN METABOLISM; REGULATORY MECHANISM; RETINA MACULA AGE RELATED DEGENERATION;

C-REACTIVE PROTEIN; CELL SEPARATION; COMPLEMENT ACTIVATION; COMPLEMENT FACTOR H; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; MACULAR DEGENERATION; MICROSCOPY, CONFOCAL; NECROSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN BINDING; PROTEIN STRUCTURE, QUATERNARY; RISK FACTORS;

EID: 80054742530     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1002488     Document Type: Article

References (42)

1. Pascolini, D., S. P. Mariotti, G. P. Pokharel, R. Pararajasegaram, D. Etya'ale, A. D. Négrel, and S. Resnikoff. 2004. 2002 global update of available data on visual impairment: a compilation of population-based prevalence studies. Ophthalmic Epidemiol. 11: 67-115. (Pubitemid 38530465)
2. Congdon, N., B. O'Colmain, C. C. Klaver, R. Klein, B. Muñoz, D. S. Friedman, J. Kempen, H. R. Taylor, and P. Mitchell; Eye Diseases Prevalence Research Group. 2004. Causes and prevalence of visual impairment among adults in the United States. Arch. Ophthalmol. 122: 477-485. (Pubitemid 38456282)
3. Jager, R. D., W. F. Mieler, and J. W. Miller. 2008. Age-related macular degeneration. N. Engl. J. Med. 358: 2606-2617.
4. Crabb, J. W., M. Miyagi, X. Gu, K. Shadrach, K. A. West, H. Sakaguchi, M. Kamei, A. Hasan, L. Yan, M. E. Rayborn, et al. 2002. Drusen proteome analysis: an approach to the etiology of age-related macular degeneration. Proc. Natl. Acad. Sci. USA 99: 14682-14687. (Pubitemid 35334544)
5. Johnson, L. V., W. P. Leitner, M. K. Staples, and D. H. Anderson. 2001. Complement activation and inflammatory processes in Drusen formation and age related macular degeneration. Exp. Eye Res. 73: 887-896. (Pubitemid 34112114)
6. Hageman, G. S., P. J. Luthert, N. H. Victor Chong, L. V. Johnson, D. H. Anderson, and R. F. Mullins. 2001. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog. Retin. Eye Res. 20: 705-732. (Pubitemid 32918285)
7. Edwards, A. O., R. Ritter, III, K. J. Abel, A. Manning, C. Panhuysen, and L. A. Farrer. 2005. Complement factor H polymorphism and age-related macular degeneration. Science 308: 421-424. (Pubitemid 40530082)
8. Haines, J. L., M. A. Hauser, S. Schmidt, W. K. Scott, L. M. Olson, P. Gallins, K. L. Spencer, S. Y. Kwan, M. Noureddine, J. R. Gilbert, et al. 2005. Complement factor H variant increases the risk of age-related macular degeneration. Science 308: 419-421. (Pubitemid 40530081)
9. Klein, R. J., C. Zeiss, E. Y. Chew, J. Y. Tsai, R. S. Sackler, C. Haynes, A. K. Henning, J. P. SanGiovanni, S. M. Mane, S. T. Mayne, et al. 2005. Complement factor H polymorphism in age-related macular degeneration. Science 308: 385-389. (Pubitemid 40530070)
10. Gold, B., J. E. Merriam, J. Zernant, L. S. Hancox, A. J. Taiber, K. Gehrs, K. Cramer, J. Neel, J. Bergeron, G. R. Barile, et al. AMD Genetics Clinical Study Group. 2006. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat. Genet. 38: 458-462.
11. Yates, J. R., T. Sepp, B. K. Matharu, J. C. Khan, D. A. Thurlby, H. Shahid, D. G. Clayton, C. Hayward, J. Morgan, A. F. Wright, et al. Genetic Factors in AMD Study Group. 2007. Complement C3 variant and the risk of age-related macular degeneration. N. Engl. J. Med. 357: 553-561. (Pubitemid 47236280)
12. Hughes, A. E., N. Orr, H. Esfandiary, M. Diaz-Torres, T. Goodship, and U. Chakravarthy. 2006. A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration. Nat. Genet. 38: 1173-1177. (Pubitemid 44470363)
13. Heinen, S., A. Hartmann, N. Lauer, U. Wiehl, H. M. Dahse, S. Schirmer, K. Gropp, T. Enghardt, R. Wallich, S. Hälbich, et al. 2009. Factor H-related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation. Blood 114: 2439-2447.
14. Fritsche, L. G., N. Lauer, A. Hartmann, S. Stippa, C. N. Keilhauer, M. Oppermann, M. K. Pandey, J. Kohl, P. F. Zipfel, B. H. Weber, and C. Skerka. 2010. An imbalance of human complement regulatory proteins CFHR1, CFHR3 and factor H influences risk for age-related macular degeneration (AMD). Hum. Mol. Genet. 19: 4694-4704.
15. 402 His) and FHL-1 in age-related macular degeneration. Mol. Immunol. 44: 3398-3406.
16. Misasi, R., H. P. Huemer, W. Schwaeble, E. Sölder, C. Larcher, and M. P. Dierich. 1989. Human complement factor H: an additional gene product of 43 kDa isolated from human plasma shows cofactor activity for the cleavage of the third component of complement. Eur. J. Immunol. 19: 1765-1768. (Pubitemid 19243900)
17. Hellwage, J., S. Kühn, and P. F. Zipfel. 1997. The human complement regulatory factor-H-like protein 1, which represents a truncated form of factor H, displays cell-attachment activity. Biochem. J. 326: 321-327. (Pubitemid 27417204)
18. Kühn, S., C. Skerka, and P. F. Zipfel. 1995. Mapping of the complement regulatory domains in the human factor H-like protein 1 and in factor H1. J. Immunol. 155: 5663-5670.
19. Kühn, S., and P. F. Zipfel. 1996. Mapping of the domains required for decay acceleration activity of the human factor H-like protein 1 and factor H. Eur. J. Immunol. 26: 2383-2387. (Pubitemid 26340939)
20. Giannakis, E., T. S. Jokiranta, D. A. Male, S. Ranganathan, R. J. Ormsby, V. A. Fischetti, C. Mold, and D. L. Gordon. 2003. A common site within factor H SCR 7 responsible for binding heparin, C-reactive protein and streptococcal M protein. Eur. J. Immunol. 33: 962-969. (Pubitemid 36546684)
21. Okemefuna, A. I., R. Nan, A. Miller, J. Gor, and S. J. Perkins. 2010. Complement factor H binds at two independent sites to C-reactive protein in acute phase concentrations. J. Biol. Chem. 285: 1053-1065.
22. 402 His polymorphism of complement factor H affects binding affinity to C-reactive protein. J. Immunol. 178: 3831-3836.
23. Ormsby, R. J., S. Ranganathan, J. C. Tong, K. M. Griggs, D. P. Dimasi, A. W. Hewitt, K. P. Burdon, J. E. Craig, J. Hoh, and D. L. Gordon. 2008. Functional and structural implications of the complement factor H Tyr402 His polymorphism associated with age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 49: 1763-1770.
24. Sjöberg, A. P., L. A. Trouw, S. J. Clark, J. Sjölander, D. Heinegård, R. B. Sim, A. J. Day, and A. M. Blom. 2007. The factor H variant associated with agerelated macular degeneration (His-384) and the non-disease-associated form bind differentially to C-reactive protein, fibromodulin, DNA, and necrotic cells. J. Biol. Chem. 282: 10894-10900. (Pubitemid 47100772)
25. Volanakis, J. E. 2001. Human C-reactive protein: expression, structure, and function. Mol. Immunol. 38: 189-197. (Pubitemid 32786776)
26. Potempa, L. A., B. A. Maldonado, P. Laurent, E. S. Zemel, and H. Gewurz. 1983. Antigenic, electrophoretic and binding alterations of human C-reactive protein modified selectively in the absence of calcium. Mol. Immunol. 20: 1165-1175. (Pubitemid 14230026)
27. Ji, S. R., Y. Wu, L. Zhu, L. A. Potempa, F. L. Sheng, W. Lu, and J. Zhao. 2007. Cell membranes and liposomes dissociate C-reactive protein (CRP) to form a new, biologically active structural intermediate: mCRP(m). FASEB J. 21: 284-294. (Pubitemid 46052567)
28. Eisenhardt, S. U., J. Habersberger, A. Murphy, Y. C. Chen, K. J. Woollard, N. Bassler, H. Qian, C. von zur Muhlen, C. E. Hagemeyer, I. Ahrens, et al. 2009. Dissociation of pentameric to monomeric C-reactive protein on activated platelets localizes inflammation to atherosclerotic plaques. Circ. Res. 105: 128-137.
29. Mihlan, M., S. Stippa, M. Józsi, and P. F. Zipfel. 2009. Monomeric CRP contributes to complement control in fluid phase and on cellular surfaces and increases phagocytosis by recruiting factor H. Cell Death Differ. 16: 1630-1640.
30. B́ró, A., Z. Rovó, D. Papp, L. Cervenak, L. Varga, G. Füst, N. M. Thielens, G. J. Arlaud, and Z. Prohászka. 2007. Studies on the interactions between Creactive protein and complement proteins. Immunology 121: 40-50.
31. Hakobyan, S., C. L. Harris, C. W. van den Berg, M. C. Fernandez-Alonso, E. G. de Jorge, S. R. de Cordoba, G. Rivas, P. Mangione, M. B. Pepys, and B. P. Morgan. 2008. Complement factor H binds to denatured rather than to native pentameric C-reactive protein. J. Biol. Chem. 283: 30451-30460.
32. Mullins, R. F., S. R. Russell, D. H. Anderson, and G. S. Hageman. 2000. Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. FASEB J. 14: 835-846. (Pubitemid 30241660)
33. Johnson, P. T., K. E. Betts, M. J. Radeke, G. S. Hageman, D. H. Anderson, and L. V. Johnson. 2006. Individuals homozygous for the age-related macular degeneration risk-conferring variant of complement factor H have elevated levels of CRP in the choroid. Proc. Natl. Acad. Sci. USA 103: 17456-17461. (Pubitemid 44788990)
34. Anderson, D. H., R. F. Mullins, G. S. Hageman, and L. V. Johnson. 2002. A role for local inflammation in the formation of drusen in the aging eye. Am. J. Ophthalmol. 134: 411-431.
35. Thurman, J. M., B. Renner, K. Kunchithapautham, V. P. Ferreira, M. K. Pangburn, Z. Ablonczy, S. Tomlinson, V. M. Holers, and B. Rohrer. 2009. Oxidative stress renders retinal pigment epithelial cells susceptible to complement-mediated injury. J. Biol. Chem. 284: 16939-16947.
36. Farkas, T. G., V. Sylvester, and D. Archer. 1971. The ultrastructure of drusen. Am. J. Ophthalmol. 71: 1196-1205.
37. Caicedo, A., D. G. Espinosa-Heidmann, Y. Piña, E. P. Hernandez, and S. W. Cousins. 2005. Blood-derived macrophages infiltrate the retina and activate Muller glial cells under experimental choroidal neovascularization. Exp. Eye Res. 81: 38-47. (Pubitemid 40840544)
38. Hotchkiss, R. S., A. Strasser, J. E. McDunn, and P. E. Swanson. 2009. Cell death. N. Engl. J. Med. 361: 1570-1583.
39. Ji, S. R., Y. Wu, L. A. Potempa, Y. H. Liang, and J. Zhao. 2006. Effect of modified C-reactive protein on complement activation: a possible complement regulatory role of modified or monomeric C-reactive protein in atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 26: 935-941.
40. Sohn, J. H., H. J. Kaplan, H. J. Suk, P. S. Bora, and N. S. Bora. 2000. Chronic low level complement activation within the eye is controlled by intraocular complement regulatory proteins. Invest. Ophthalmol. Vis. Sci. 41: 3492-3502.
41. Zipfel, P. F., and C. Skerka. 2009. Complement regulators and inhibitory proteins. Nat. Rev. Immunol. 9: 729-740.
42. Krysko, O., L. De Ridder, and M. Cornelissen. 2004. Phosphatidylserine exposure during early primary necrosis (oncosis) in JB6 cells as evidenced by immunogold labeling technique. Apoptosis 9: 495-500. (Pubitemid 38987586)